Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis.
Adolescent
Adult
Bacteroidaceae Infections
/ drug therapy
Clindamycin
/ pharmacology
Drug Resistance, Bacterial
/ drug effects
Female
Gardnerella vaginalis
Gram-Positive Bacterial Infections
/ drug therapy
Humans
Hydrogen Peroxide
/ metabolism
Lactic Acid
/ metabolism
Lactobacillus
/ genetics
Metronidazole
/ pharmacology
Prevotella
South Africa
Species Specificity
Vaginosis, Bacterial
/ drug therapy
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
07
06
2019
accepted:
16
04
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Antibiotics continue to be the standard-of-care for bacterial vaginosis (BV), although recurrence rates are high. Vaginal probiotics may improve durability of BV treatment, although few probiotics for vaginal health contain Lactobacillus spp. that commonly colonize the lower female genital tract. Characteristics of vaginal Lactobacillus strains from South African women were evaluated for their probiotic potential in vitro compared to strains from commercial vaginal products, including growth at varying pHs, ability to lower pH, produce D-/L-lactate and H2O2, influence growth of BV-associated Gardnerella vaginalis and Prevotella bivia, adherence to cervical cells and susceptibility to antibiotics. Fifty-seven Lactobacillus strains were purified from cervico-vaginal fluid, including L. crispatus, L. jensenii, L. gasseri, L. mucosae, and L. vaginalis. L crispatus strains grew better at pHs below 4.5 and lowered pH more effectively than other strains. Production of D-/L-lactate and H2O2 varied between Lactobacillus species and strains. Lactobacillus strains generally inhibited P. bivia more uniformly than G. vaginalis isolates. All vaginal Lactobacillus isolates were resistant to metronidazole while susceptibility to clindamycin varied. Furthermore, vaginal Lactobacillus strains tended to be broadly susceptible to penicillin, amoxicillin, rifampicin and rifabutin. Whole-genome-sequencing of five of the best-performing vaginal Lactobacillus strains confirmed their likely safety, due to antimicrobial resistance elements being largely absent, while putative intact prophages were present in the genomes of two of the five strains. Overall, vaginal Lactobacillus strains largely performed better in these in vitro assays than probiotic strains currently used in probiotics for vaginal health. Including the best-performing vaginal Lactobacillus isolates in a region-specific probiotic for vaginal health may result in improved BV treatment options.
Identifiants
pubmed: 32497109
doi: 10.1371/journal.ppat.1008559
pii: PPATHOGENS-D-19-01020
pmc: PMC7271994
doi:
Substances chimiques
Metronidazole
140QMO216E
Lactic Acid
33X04XA5AT
Clindamycin
3U02EL437C
Hydrogen Peroxide
BBX060AN9V
Types de publication
Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008559Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hum Reprod. 2001 Sep;16(9):1809-13
pubmed: 11527880
J Bacteriol. 2014 Apr;196(7):1458-70
pubmed: 24488312
Curr Microbiol. 2005 Apr;50(4):202-7
pubmed: 15902467
Nucleic Acids Res. 2016 Jul 8;44(W1):W16-21
pubmed: 27141966
Bioinformatics. 2013 Apr 15;29(8):1072-5
pubmed: 23422339
J Infect Dis. 1996 Nov;174(5):1058-63
pubmed: 8896509
Sci Rep. 2015 Jun 26;5:11640
pubmed: 26113465
Nat Rev Immunol. 2010 Feb;10(2):89-102
pubmed: 20081871
FEMS Immunol Med Microbiol. 2003 Mar 20;35(2):131-4
pubmed: 12628548
Front Microbiol. 2013 Jul 18;4:202
pubmed: 23882264
Sci Rep. 2016 Jun 29;6:29024
pubmed: 27354249
Curr Opin Virol. 2016 Aug;19:85-91
pubmed: 27497036
J Appl Microbiol. 2005;98(3):775-82
pubmed: 15715882
Med Mal Infect. 2017 Nov;47(7):477-483
pubmed: 28797834
Nucleic Acids Res. 2014 Jan;42(Database issue):D206-14
pubmed: 24293654
Clin Ther. 2008 Mar;30(3):453-68
pubmed: 18405785
Sci Transl Med. 2012 May 2;4(132):132ra52
pubmed: 22553250
Trends Microbiol. 2017 Mar;25(3):182-191
pubmed: 27914761
BMC Womens Health. 2017 Jan 19;17(1):7
pubmed: 28103868
Br J Biomed Sci. 2005;62(4):170-4
pubmed: 16411376
Microb Ecol Health Dis. 2016 Aug 12;27:30484
pubmed: 27527701
Infect Dis Obstet Gynecol. 2008;2008:549640
pubmed: 19190778
Am J Obstet Gynecol. 2001 Aug;185(2):375-9
pubmed: 11518895
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1269-74
pubmed: 22232693
Mutat Res. 2000 Mar 3;466(1):57-62
pubmed: 10751726
Clin Diagn Lab Immunol. 2001 Jan;8(1):31-9
pubmed: 11139192
J Infect Dis. 2012 Jul 1;206(1):6-14
pubmed: 22517910
FEMS Immunol Med Microbiol. 2006 Dec;48(3):424-32
pubmed: 17059467
J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):203-10
pubmed: 18520679
J Acquir Immune Defic Syndr. 2010 Aug;54(5):463-9
pubmed: 20577090
J Bacteriol. 1991 Jan;173(2):697-703
pubmed: 1987160
Res Microbiol. 2017 Nov - Dec;168(9-10):782-792
pubmed: 28435139
Nucleic Acids Res. 2020 Jan 8;48(D1):D517-D525
pubmed: 31665441
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Paediatr Perinat Epidemiol. 2014 Mar;28(2):88-96
pubmed: 24405280
Int J Food Microbiol. 2004 Mar 15;91(3):253-60
pubmed: 14984773
J Antimicrob Chemother. 2012 Nov;67(11):2640-4
pubmed: 22782487
Infect Dis Obstet Gynecol. 2001;9(1):41-5
pubmed: 11368258
Infect Dis Obstet Gynecol. 1994;2(4):179-83
pubmed: 18475388
BMC Infect Dis. 2011 Jul 19;11:200
pubmed: 21771337
RNA Biol. 2013 May;10(5):817-27
pubmed: 23492433
Nucleic Acids Res. 2018 Jul 2;46(W1):W246-W251
pubmed: 29790974
Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1869-1880
pubmed: 30032443
J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S106-12
pubmed: 25291116
Front Microbiol. 2011 Sep 28;2:203
pubmed: 22046172
Clin Infect Dis. 1993 Jun;16 Suppl 4:S273-81
pubmed: 8324131
Bioinformatics. 2015 Dec 1;31(23):3733-41
pubmed: 26261222
Clin Infect Dis. 2016 Oct 1;63(7):853-67
pubmed: 27621353
J Med Microbiol. 2012 Aug;61(Pt 8):1074-1081
pubmed: 22539000
Int Microbiol. 2009 Jun;12(2):131-6
pubmed: 19784933
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Am J Obstet Gynecol. 2007 Aug;197(2):170.e1-7
pubmed: 17689638
Clin Infect Dis. 2015 Jul 15;61(2):260-9
pubmed: 25900168
J Antimicrob Chemother. 2013 Sep;68(9):2015-25
pubmed: 23657804
mBio. 2011 Oct 25;2(6):e00168-11
pubmed: 22027006
Immunity. 2015 May 19;42(5):965-76
pubmed: 25992865
AIDS Res Hum Retroviruses. 2019 Mar;35(3):219-228
pubmed: 30638028
Int J Gynaecol Obstet. 2010 Sep;110(3):223-6
pubmed: 20573348
Am J Obstet Gynecol. 2002 Sep;187(3):561-8
pubmed: 12237628
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Microbiome. 2018 Feb 06;6(1):29
pubmed: 29409534
Appl Environ Microbiol. 1996 Mar;62(3):1089-92
pubmed: 8975601
Infect Immun. 1999 Oct;67(10):5170-5
pubmed: 10496892
PLoS Med. 2012;9(6):e1001251
pubmed: 22745608
J Food Prot. 1998 Dec;61(12):1636-43
pubmed: 9874341
Diagn Microbiol Infect Dis. 1993 Feb;16(2):111-8
pubmed: 8385592
Infect Dis Obstet Gynecol. 2006;2006:18182
pubmed: 17485797
Sex Transm Infect. 2016 Sep;92(6):441-6
pubmed: 26825087
Microbes Infect. 2000 Apr;2(5):543-6
pubmed: 10865199
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31427293
Int J STD AIDS. 2018 May;29(6):531-539
pubmed: 29198180
Infect Immun. 2017 Dec 19;86(1):
pubmed: 29038128
Arch Microbiol. 2011 Mar;193(3):157-68
pubmed: 21193902
Iran J Microbiol. 2010 Sep;2(3):147-54
pubmed: 22347564
Antimicrob Agents Chemother. 1993 Dec;37(12):2733-5
pubmed: 8109944
Can J Microbiol. 2009 Feb;55(2):133-8
pubmed: 19295645
mBio. 2013 Aug 06;4(4):
pubmed: 23919998